Compare Linde PLC (LIN) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Linde PLC vs Sanofi SA — how do they compare? Linde PLC trades at $511.96 (market cap $236.74B), while Sanofi SA trades at $43.94 (market cap $104.83B). The key difference: Linde PLC is far larger — about 2.3× Sanofi SA's market cap, and Sanofi SA pays the higher dividend (5.5%). Which is the better fit depends on your goals.
| LIN | SNY | |
|---|---|---|
Market Cap | $236.74B | $104.83B |
Sector | Basic Materials | Health |
52-Week High | $546.64 | $52.34 |
52-Week Low | $389.38 | $41.33 |
Enterprise Value | $259.10B | $121.32B |
Dividend Yield | 1.25% | 5.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Linde (LIN) trades at $512.05, down 0.2% on the day, with strong fundamentals including 20.44% net income margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with revenue growth to $34.0B in 2025. Recent Q1 2026 results showed EPS of $4.33 beating estimates, while analyst consensus remains strongly bullish with 89% buy ratings and a $564.80 price target.
LIN presents a compelling long-term investment with premium valuation metrics offset by exceptional profitability and dividend growth. Key risks include elevated debt levels (debt-to-asset ratio rising to 31.63% in 2025) and potential margin pressure from economic cycles. The current technical weakness may offer entry points for investors seeking quality industrial exposure with sustainable growth prospects.
SNY trades at $43.97, down 1.55% today, with a bullish technical signal supported by moving averages. The company reported strong Q1 2026 earnings of $1.10 per share, beating expectations, and maintains robust profitability with a 71.92% gross margin. Recent FDA approval for Sarclisa's subcutaneous formulation and expanded AI research collaboration with Aqemia highlight ongoing innovation. Cash flow from operations remains healthy at $10.75 billion for 2025, though net cash flow is minimal at $49 million.
SNY presents a balanced investment case with solid fundamentals and analyst support (44% buy ratings), but faces risks from EU antitrust probes and patent expiration concerns for key drug Dupixent. Valuation metrics appear reasonable with P/E of 19.81 and P/B of 1.29. The stock's outlook depends on successful drug pipeline execution and navigating regulatory challenges, with current price levels offering stability near support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Linde PLC
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.
Read more on LIN →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
